Cargando…
The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients
Introduction Fabry disease is a metabolic storage disorder that causes disorders in multiple organs including the brain. Data regarding the prevalence of the disease among the Saudi stroke population is scarce. Hence, tests for the same are not conducted on a regular basis when investigating stroke...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450207/ https://www.ncbi.nlm.nih.gov/pubmed/32864243 http://dx.doi.org/10.7759/cureus.9415 |
_version_ | 1783574769274191872 |
---|---|
author | Alhazzaa, Mohammed A Mujtaba, Ahmed Aljohani, Mohammed A Alqarni, Fatimah Alsharif, Roaa |
author_facet | Alhazzaa, Mohammed A Mujtaba, Ahmed Aljohani, Mohammed A Alqarni, Fatimah Alsharif, Roaa |
author_sort | Alhazzaa, Mohammed A |
collection | PubMed |
description | Introduction Fabry disease is a metabolic storage disorder that causes disorders in multiple organs including the brain. Data regarding the prevalence of the disease among the Saudi stroke population is scarce. Hence, tests for the same are not conducted on a regular basis when investigating stroke of uncertain cause. Our study aimed to provide insight into whether testing for Fabry disease is justifiable in cryptogenic stroke patients who have no other features of the disease. Method This was a prospective study conducted at a single stroke center. We included young patients between the ages of 18 and 55 years who had confirmed and unexplained ischemic or hemorrhagic insults. Alpha-galactosidase enzyme testing was conducted in all suspected cases. Further genetic testing was performed in patients with abnormal enzyme results. Result A total of 51 patients met the inclusion criteria. The mean age was 42 years. All the included patients completed a workup of ischemia or hemorrhage. All cases had no clear etiology of their vascular events. All included patients lacked classic systemic manifestations of Fabry disease. We identified one case of borderline low α-galactosidase A (GLA) enzyme level. However, GLA genetic testing did not reveal any Fabry disease-related mutation. The study did not identify any subject with confirmed Fabry disease. Conclusion In this single-center study, we found that Fabry disease had a low prevalence among Saudi cryptogenic stroke patients who lack other systemic manifestations. Hence, Fabry testing is not generally considered in routine workup related to cryptogenic stroke. |
format | Online Article Text |
id | pubmed-7450207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-74502072020-08-28 The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients Alhazzaa, Mohammed A Mujtaba, Ahmed Aljohani, Mohammed A Alqarni, Fatimah Alsharif, Roaa Cureus Neurology Introduction Fabry disease is a metabolic storage disorder that causes disorders in multiple organs including the brain. Data regarding the prevalence of the disease among the Saudi stroke population is scarce. Hence, tests for the same are not conducted on a regular basis when investigating stroke of uncertain cause. Our study aimed to provide insight into whether testing for Fabry disease is justifiable in cryptogenic stroke patients who have no other features of the disease. Method This was a prospective study conducted at a single stroke center. We included young patients between the ages of 18 and 55 years who had confirmed and unexplained ischemic or hemorrhagic insults. Alpha-galactosidase enzyme testing was conducted in all suspected cases. Further genetic testing was performed in patients with abnormal enzyme results. Result A total of 51 patients met the inclusion criteria. The mean age was 42 years. All the included patients completed a workup of ischemia or hemorrhage. All cases had no clear etiology of their vascular events. All included patients lacked classic systemic manifestations of Fabry disease. We identified one case of borderline low α-galactosidase A (GLA) enzyme level. However, GLA genetic testing did not reveal any Fabry disease-related mutation. The study did not identify any subject with confirmed Fabry disease. Conclusion In this single-center study, we found that Fabry disease had a low prevalence among Saudi cryptogenic stroke patients who lack other systemic manifestations. Hence, Fabry testing is not generally considered in routine workup related to cryptogenic stroke. Cureus 2020-07-27 /pmc/articles/PMC7450207/ /pubmed/32864243 http://dx.doi.org/10.7759/cureus.9415 Text en Copyright © 2020, Alhazzaa et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Neurology Alhazzaa, Mohammed A Mujtaba, Ahmed Aljohani, Mohammed A Alqarni, Fatimah Alsharif, Roaa The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients |
title | The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients |
title_full | The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients |
title_fullStr | The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients |
title_full_unstemmed | The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients |
title_short | The Prevalence of Fabry Disease Among Young Cryptogenic Stroke Patients |
title_sort | prevalence of fabry disease among young cryptogenic stroke patients |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450207/ https://www.ncbi.nlm.nih.gov/pubmed/32864243 http://dx.doi.org/10.7759/cureus.9415 |
work_keys_str_mv | AT alhazzaamohammeda theprevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients AT mujtabaahmed theprevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients AT aljohanimohammeda theprevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients AT alqarnifatimah theprevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients AT alsharifroaa theprevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients AT alhazzaamohammeda prevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients AT mujtabaahmed prevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients AT aljohanimohammeda prevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients AT alqarnifatimah prevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients AT alsharifroaa prevalenceoffabrydiseaseamongyoungcryptogenicstrokepatients |